Plain-English translation of NCT04513639 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tests whether patients with newly diagnosed multiple myeloma (a blood cancer) should restart second-line treatment early—as soon as sensitive blood tests show the cancer returning—or wait until the disease clearly progresses. All participants receive standard first-line chemotherapy with bortezomib, lenalidomide, and dexamethasone, followed by stem cell transplant. Those who achieve complete remission are then randomly assigned to one of two monitoring strategies, both using the same second-line medication (carfilzomib, dexamethasone, and daratumumab) when treatment is needed.
Researchers want to know whether catching early signs of cancer return with sensitive blood tests and restarting treatment right away helps patients live longer and stay healthier, compared to waiting until the disease becomes measurable again using standard methods.
You likely qualify if…
You likely don't qualify if…
Participants receive four cycles of combination chemotherapy before transplant, then undergo one or two stem cell transplants depending on how they respond. After transplant, they receive four more cycles of consolidation therapy. Those who achieve complete remission are randomly assigned to either intensive monitoring with blood tests every 4 months and early treatment restart, or standard monitoring with treatment restart only if disease clearly progresses. Whichever group you're in, you'll receive the same second-line medication when needed and continue until the disease progresses or side effects become too difficult to manage.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Norway